You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Exchange transfusion and intravenous immunoglobulin use in the UK
  1. G Y T Ng1,
  2. I Roberts2,
  3. H V New3
  1. 1
    Department of Neonatology, St Mary’s Hospital, London, UK
  2. 2
    Department of Haematology, Imperial College Healthcare NHS Trust, London, UK
  3. 3
    Department of Paediatrics, St Mary’s Hospital, London, UK
  1. Correspondence to Geraldine Ng, Department of Neonatology, 1st Floor, The Bays Building, Imperial College Healthcare NHS Trust, St Mary’s Hospital, Praed Street, London W2 1NY, UK; geraldine.ng{at}imperial.nhs.uk

https://doi.org/10.1136/adc.2009.162123

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Phototherapy and exchange blood transfusion are primary treatment modes for significant haemolytic disease of the newborn (HDN), to lower serum bilirubin and reduce risk of kernicterus.1 Incidence of HDN has decreased in recent years and there has been concern over decreased experience in performing exchange transfusions.2

    The American Academy of Pediatrics recommends intravenous immunoglobulin (IVIG) use for newborns with HDN due to Rh and ABO incompatibility and rising bilirubin.3 IVIG may be an alternative to exchange transfusion to avoid some …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and Peer review Not commissioned; not externally peer reviewed.